Table 4.

The overall survival of miRNAs in enrolled studies

miRNA	Samples	OS HR/RR (95%CI)	P value	Refs
miR‐23a	3 pairs of primary prostate cancer and adjacent non‐tumor tissues 20 paired of prostate cancer and adjacent non‐tumor tissues. 123 prostate cancer tissues	0.389 (0.249‐0.608)	<0.001	41
miR‐23b	118 pairs of PCs and controls 27 BPH and 20 tumor samples 48 samples	3.3 (4‐19)	<0.0001	43
miR‐132	Phase 1 cohort: 97 patients Phase 2 cohort: 89 patients	1.9 (1.1‐3.4)	0.02	29
miR‐150	167 PC 4 pairs of PC and adjacent normal tissues	1.87 (1.19‐2.94)	0.006	63
miR‐200a	Phase 1 cohort: 97 patients Phase 2 cohort: 89 patients	2.1 (1.2‐3.6)	0.009	29
miR‐200b	Phase 1 cohort: 97 patients Phase 2 cohort: 89 patients	3.8 (2.0‐6.9)	0.000006	29
miR‐200c	Phase 1 cohort: 97 patients Phase 2 cohort: 89 patients	3.8 (2.0‐6.9)	0.005	29
miR‐205	Study cohort: 105 HRPC, 10 BPH validation cohort: 78 HRPC	Study cohort: 2.04 Validation cohort: 3.1	0.0817	71
miR‐221	cohort 1: 134 PC cohort 2: 89 PC	cohort 1: 0 cohort 2: 0.029	<0.0001	74
miR‐224	4 and 20 pairs of primary PC and adjacent non‐tumor Taylor dataset: 149 primary PC tissues and 29 adjacent non‐cancerous prostate tissues	0.73 (0.31‐1.72)	0.046	76
miR‐429	Phase 1 cohort: 97 patients Phase 2 cohort: 89 patients	3.3 (1.8‐6.0)	0.00005	29
miR‐708	40 PC and 8 normal 96 pairs of PC and normal	6 (2.2‐16.4)	0.0223	92
miR‐1207‐3p	PC patients of 389 CA and 15 AA	1.8 (0.8‐4.3)	0.062	93
miR‐1290	23 CRPC patients 100 CRPC	1.79 (1.30‐2.48)	<0.004	30

OS,overall survival; HR, hazard ratio; CI, confidence interval; Refs, reference; PC, prostate cancer; BPH, benign prostate hyperplasia; CRPC, castration resistant prostate cancer.